Form 4: Y-mAbs Therapeutics CFO Peter Pfreundschuh Receives Stock Options and Restricted Stock Units

Y-mAbs Therapeutics CFO and Treasurer, Peter Pfreundschuh, was granted stock options and restricted stock units as part of the company's 2018 Equity Incentive Plan.

Summary

• Peter Pfreundschuh, CFO and Treasurer of Y-mAbs Therapeutics, received 31,800 restricted stock units (RSUs) and 63,500 stock options on January 17, 2025.
• The RSUs will vest in three equal installments on January 17, 2026, 2027, and 2028, contingent on continued service.
• The stock options vest as to 25% on January 17, 2026, and then in equal monthly installments until fully vested, also contingent on continued service.
• The stock options have an exercise price of $6.16 and expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative surprises or concerns.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Y-mAbs Therapeutics' stock price.
• The vesting of the options and RSUs is contingent on the CFO's continued employment with the company.

Future Outlook

The vesting of the stock options and RSUs is contingent on the CFO's continued service to the company.

Industry Context

The granting of stock options and restricted stock units is a common practice for incentivizing executives in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• Vesting schedules are typically structured to encourage long-term performance and retention, similar to what is outlined in this document.
• Companies like BioMarin Pharmaceutical Inc. and Regeneron Pharmaceuticals Inc. also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity incentive plan, executive compensation, insider trading, form 4, Y-mAbs Therapeutics, YMAB